Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: Normalization by atorvastatin
- 7 April 2004
- journal article
- clinical trial
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 43 (7), 1188-1194
- https://doi.org/10.1016/j.jacc.2003.10.046
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Anti-inflammatory and immunomodulatory effects of statinsKidney International, 2003
- Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemiaAtherosclerosis, 2002
- Fas Ligand-deficient Mice Display Enhanced Leukocyte Infiltration and Intima Hyperplasia in Flow-restricted VesselsJournal of Molecular and Cellular Cardiology, 2000
- Elevated circulating levels and cardiac secretion of soluble fas ligand in patients with congestive heart failureThe American Journal of Cardiology, 1999
- Soluble Fas (APO‐1, CD95) and soluble Fas ligand in rheumatic diseasesArthritis & Rheumatism, 1997
- Apoptosis by Death FactorCell, 1997
- Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover.The Journal of cell biology, 1996
- Metalloproteinase-mediated release of human Fas ligand.The Journal of Experimental Medicine, 1995
- Fas Ligand-Induced Apoptosis as a Mechanism of Immune PrivilegeScience, 1995
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993